The findings of the economic evaluation support the potential cost-effectiveness of BRCA1/BRCA2 genetic testing on a broader scale in the Canadian general population, which could prevent thousands more BC and OC diagnoses and deaths than FH-based testing. This evidence concerns the gene BRCA1 and breast cancer.